Abstract:
Thrombin-activated Fibrinolysis inhibitor (TAFI), participates in the regulation
of the balance between coagulation and fibrinolysis. High plasma levels of TAFI may therefore
contribute to a hyperfibrinolytic condition and an increased risk of thrombotic disorders.
Coronary stenosis is a consequence of the progression of atherosclerotic plaques, which is
associated with a violation of fibrinolysis. Thrombin-activated fibrinolysis inhibitor (TAFI) and
plasminogen activator 1 inhibitor (PAI-1) are fibrinolysis inhibitors whose levels depend on
acquired conditions and polymorphisms. Therefore, our study is aimed at studying the association
of TAFI gene polymorphism with the severity of coronary stenosis in patients with stable coronary
artery disease (CAD).
The methods that have recently appeared for determining alleles of polymorphic genetic
markers using polymerase chain reaction will allow us to assess the genetic risk of developing
cardiovascular pathology especially for the purpose of primary prevention of coronary heart
disease, as well as to improve new approaches to individualization of therapy as a secondary
prevention of the disease.
